Original Research

A Treatment Protocol for Patients With Diabetic Peripheral Neuropathy

Author and Disclosure Information

 

References

Acknowledgements
Clinical support was provided by David Metzelfeld, DPT, and Cam Lendrim, PTA of William Jennings Bryan Dorn VA Medical Center. Paul Bartels, PhD, of Warren Wilson College provided data analysis support. Anodyne Therapy, LLC, provided the MIRE unit used in the clinic.

Author disclosures
The authors report no actual or potential conflicts of interest with regard to this article.

Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner , Frontline Medical Communications Inc., the U.S. Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.

Pages

Recommended Reading

Finerenone cuts albuminuria in diabetic nephropathy
Type 2 Diabetes ICYMI
VIDEO: Newer Type 2 Diabetes Drugs Pose No Significant Heart Failure Risk
Type 2 Diabetes ICYMI
Diabetes prevalence rising, especially in black, Asian, and Hispanic populations
Type 2 Diabetes ICYMI
HbA1c aids prediction of atherosclerotic CVD
Type 2 Diabetes ICYMI
High-calorie American diet causes insulin resistance within days
Type 2 Diabetes ICYMI
So much sugar in long-term care
Type 2 Diabetes ICYMI
FDA issues revised warning for adverse effects associated with canagliflozin
Type 2 Diabetes ICYMI
Diabetes Prevalence Rising, Especially in Black, Asian, and Hispanic Populations
Type 2 Diabetes ICYMI
High-calorie American Diet Causes Insulin Resistance Within Days
Type 2 Diabetes ICYMI
ESC: Further data indicate no excess heart failure risk with lixisenatide or sitagliptin
Type 2 Diabetes ICYMI